Paolo Marcucci was appointed Chairman and CEO of BPL in August 2022.
A lifelong entrepreneur and a corporate leader in the biopharmaceuticals sector, Paolo co-founded Kedrion Biopharma in 2001. He received a degree in Economics, and an MBA at EDHEC Business School. His professional passions have always included business development and strategy.
From 2006, Paolo has been the Chairman and CEO of Kedrion Biopharma, and has been the founder and CEO of several other companies, especially in the pharma and telecommunications sectors.
Paolo has always been committed to putting patients first in everything that Kedrion does, and he will bring to BPL the same spirit in order to meet the needs of patients everywhere who can benefit from plasma-derived therapies. His vision of the new and combined group, which includes both BPL and Kedrion, is to foster future global growth through both organic and acquisitions-led growth, but above all by remaining committed to excellence.
Paolo has been serving on the PPTA (Plasma Protein Therapeutics Association) Global Board of Directors since 2008 and was Chairman of PPTA Global Board from 2013 to 2015. He is married and has two daughters.